Connect with us
DAPA Banner

Crypto World

Hims & Hers (HIMS) Stock Plummets 39% Amid GLP-1 Strategy Shift and Margin Pressure

Published

on

HIMS Stock Card

Key Takeaways

  • In March 2026, Hims & Hers transitioned away from compounded semaglutide to FDA-approved branded GLP-1 medications
  • Bank of America reduced its HIMS price target to $21 from $23 while maintaining a Neutral stance
  • Analysts project GLP-1 EBITDA contributions may decline by 50% compared to last year
  • Amazon Pharmacy launched Eli Lilly’s oral GLP-1 medication Foundayo, intensifying market competition
  • Year-to-date, HIMS shares have plunged approximately 39%, hovering near $20

In a significant strategic shift this March, Hims & Hers abandoned its compounded semaglutide offerings in favor of FDA-sanctioned branded GLP-1 treatments. Management positioned this decision as transforming the company into “the largest global consumer health platform for access to more affordable, approved medications.”


HIMS Stock Card
Hims & Hers Health, Inc., HIMS

This strategic reversal came after settling legal proceedings with Novo Nordisk. The resolution required Hims & Hers to distribute Novo Nordisk’s authorized GLP-1 medications instead of less expensive compounded alternatives.

Investors have responded harshly to these developments. HIMS shares have plummeted nearly 39% year-to-date through Wednesday, currently trading in the vicinity of $20.

BofA Securities analyst Allen Lutz reduced his price objective on HIMS this week from $23 down to $21. The analyst maintained his Neutral stance, pointing to valuation compression among comparable companies and anticipated near-term profitability headwinds.

Lutz’s forecast suggests 2026 EBITDA could land approximately 20% beneath current Wall Street expectations. His analysis indicates GLP-1-related EBITDA contributions might decline by up to 50% compared to the previous year.

Advertisement

Neverthstanding the conservative perspective, Lutz indicated his research team holds “slightly more optimistic” views regarding the company’s overseas expansion strategy. He further observed that the $149 monthly branded GLP-1 subscription plan might eventually deliver margins comparable to compounded options, contingent upon subscriber migration rates.

Subscriber Migration Rates Will Determine Success

BofA Securities projects that Hims & Hers might successfully transition between 40% and 50% of current subscribers to branded medication plans, while maintaining 5% to 10% on compounded alternatives. This conversion scenario would produce approximately $60 million to $90 million in GLP-1 revenues each quarter.

The telehealth platform is simultaneously pursuing international market opportunities. Management targets growing this division beyond $1 billion in annual revenue within a three-year timeframe, achieving mid-teens organic compound annual growth rates. Bank of America’s research into the Eucalyptus platform indicates approximately 90% of revenues will derive from branded GLP-1 distribution at roughly 40% gross profit margins.

Canaccord analyst Maria Ripps offered a more bullish assessment. She maintained her Buy recommendation, contending that the Novo Nordisk collaboration represents a “long-term tailwind” for the business. Ripps believes current valuations fail to recognize the value of the company’s telehealth infrastructure, customer base, and broadening treatment offerings.

Advertisement

Amazon Intensifies Competition With Foundayo Launch

Competitive dynamics became more challenging Thursday when Amazon Pharmacy revealed plans to distribute Eli Lilly’s recently authorized oral GLP-1 medication, Foundayo, featuring same-day delivery options. HIMS shares dipped 0.5% following this announcement. Novo Nordisk declined 1.5%.

Foundayo represents a once-daily oral therapy designed for adults managing obesity or overweight conditions with related health complications. Pricing begins at $25 monthly with insurance coverage, or $149 monthly for self-pay patients.

Amazon will provide same-day delivery across nearly 3,000 metropolitan areas, with plans to extend coverage to 4,500 locations before year-end. The e-commerce giant disclosed it has distributed GLP-1 medications since 2021, with customers saving over $200 million through automated coupon programs, where GLP-1 treatments represent the largest savings category.

Wall Street consensus on HIMS currently stands at Moderate Buy, based on four Buy ratings and 10 Hold ratings issued during the past three months. The mean price target of $26.36 suggests potential upside of approximately 36% from present trading levels.

Advertisement

Source link

Continue Reading
Click to comment

You must be logged in to post a comment Login

Leave a Reply

Crypto World

How $5K Could Hit $750K as RaveDAO Prints 250% and Pepeto Targets 150x While DOGE and LINK Hold

Published

on

How $5K Could Hit $750K as RaveDAO Prints 250% and Pepeto Targets 150x While DOGE and LINK Hold

The crypto news landed hard this week when RaveDAO exploded 250% on April 10, driven by months of quiet accumulation after its Coinbase debut. One listing turned an overlooked token into a $300 million asset overnight. Large caps barely moved while the listed projects printed gains that changed portfolios.

The presale is next in line with $8.9 million already raised, a running exchange, and a confirmed Binance listing ahead. At today’s entry, $5,000 converts to over 26 billion tokens, and if the price reaches what Pepe hit on the same 420 trillion supply, that is 150x, turning $5,000 into $750,000.

RaveDAO gained 250% in a single session on April 10, pushing past $300 million in market cap after its February Coinbase listing created the foundation for a breakout, according to CoinMarketCap.

Overbought readings on the chart raised caution flags around the speed of the move, a pattern common after sudden listing-driven spikes, according to CoinGecko.

Advertisement

Every wallet that positioned in RaveDAO ahead of its Coinbase debut walked away with the gains. The wallets that showed up after the spike are now holding bags at elevated prices.

DOGE, LINK, Pepeto, and Where One Listing Turns Small Entries Into Real Wealth

Pepeto

The crypto news keeps proving that the market rewards the tools it can rely on. The exchange was built to solve a real problem, screening tokens for exploits and traps so traders stop losing money to scam contracts that look normal on the surface.

A full contract audit runs before any trade executes, checking for drain functions, honeypot code, and fake supply manipulation. Results appear in clear language anyone can read. Trades clear through PepetoSwap with no fee attached, and the bridge shifts tokens across chains without deducting anything from the transfer.

The numbers tell the story the crypto news has not printed yet. Over 26 billion tokens at $0.000000186 for $5,000. Pepe reached $0.00002803 on 420 trillion tokens and no working product. Reaching that same level from today’s presale price means 150x, which sends $5,000 to $750,000.

Advertisement

The exchange already runs, the SolidProof audit is done, a Binance operations veteran sits on the team, the creator of the original Pepe token built every tool, and 185% APY staking grows each position while stages close. When the listing drops, the crypto news will cover Pepeto the way it covered RaveDAO this week, and you are either positioned or you are not.

Dogecoin (DOGE) Price at $0.093 as Commodity Status Is Official but Buyers Stay Away

Dogecoin (DOGE) sits at $0.093 per CoinMarketCap, down 0.26% after the SEC finalized its commodity classification without triggering fresh demand.

DOGE must clear $0.102 before any bounce holds, with $0.087 acting as the floor. The token once ran from $0.007 to a $90 billion cap, but at current levels a strong run delivers 2x to 3x over months. A presale priced for 150x from a single listing offers a different equation entirely.

Chainlink (LINK) Price at $9.10 as Bitwise ETF Opens LINK to Retirement Accounts

Chainlink (LINK) trades at $9.10 per CoinMarketCap, gaining 2% after the Bitwise LINK ETF (CLNK) launched on NYSE Arca and opened LINK to 401(k) and IRA holders for the first time.

Advertisement

Support holds at $8.50, resistance at $9.50, with CCIP now processing $18 billion in monthly volume. Analysts target $15 by late 2026, a solid double that takes months to arrive. A presale listing compresses that kind of gain into days instead of quarters.

Conclusion

You sat through the last cycle and watched other wallets collect while you waited for a better price that never came. You told yourself next time would be different, and this is next time. The crypto news this week showed RaveDAO printing 250% from a listing while DOGE holds $0.093 and LINK sits deep in fear.

The stages are filling faster now, and every one that closes raises the floor for the next. The Binance listing is not a theory. It is confirmed and approaching. Pepeto’s official site is where the decision gets made, and a 2026 portfolio without this entry is the mistake you take into 2027 the same way last cycle’s hesitation followed you into this year.

Click To Visit Pepeto Website To Enter The Presale

Advertisement

FAQs

What is the latest crypto news about listing events and presale returns in 2026?

RaveDAO gained 250% after its Coinbase listing this week while Pepeto heads toward a Binance listing with $8.9 million raised and 150x projected by analysts.

Is Dogecoin (DOGE) at $0.093 a better entry than Pepeto at presale pricing?

DOGE must break $0.102 for recovery and offers 2x to 3x over months at best. Pepeto targets 150x from a presale price of $0.000000186 with one listing event ahead.

Advertisement

Disclaimer: This is a Press Release provided by a third party who is responsible for the content. Please conduct your own research before taking any action based on the content.

Source link

Continue Reading

Crypto World

Trump-Linked Crypto Tokens Face Renewed Scrutiny After Plummeting in Price

Published

on

Donald Trump, Trumpcoin, Memecoin

United States President Donald Trump is facing renewed scrutiny, as crypto tokens and projects promoted by the US president crash to all-time lows or sit near record low levels.

The Official Trump token (TRUMP), a memecoin promoted by Trump, hit an all-time low of about $2.73 in March 2026 and is currently trading at about $2.86, according to data from CoinGecko.

Donald Trump, Trumpcoin, Memecoin
The TRUMP memecoin has plummeted in price since launching in January 2025. Source: CoinGecko

World Liberty Financial (WLFI), a decentralized finance (DeFi) platform co-founded by Trump’s sons, also issued a governance token, which crashed to an all-time low on Saturday, falling to just $0.07.

WLFI is down by nearly 75% from its all-time high of about $0.31 reached in September 2025, while the TRUMP memecoin is down by about 90% since its all-time high of over $73 reached in January 2025. 

Donald Trump, Trumpcoin, Memecoin
The WLFI token has crashed by nearly 75% since the all-time high reached in September 2025. Source: CoinMarketCap

“We thought Sam Bankman-Fried or Gary Gensler were the worst things to happen to the crypto industry, and they were horrible,” Professor Tonya Evans said in response to the plummeting token prices. She added:

“But, turns out, it was the guy who surrounds himself with sycophants, siphons every bit of value he can for himself, and then expeditiously bankrupts companies and casinos without consequence.”

President Trump also announced another gala for token holders, scheduled to take place on April 25, fueling renewed scrutiny from US Democratic lawmakers, who have accused Trump of influence peddling by giving token holders access to him.

Advertisement

Related: Trump memecoin whales pile in ahead of Mar-a-Lago gala

US lawmakers send letter to Trump memecoin creator

Senators Elizabeth Warren, Richard Blumenthal and Adam Schiff recently sent a letter to Bill Zanker, the individual who launched the Trump memecoin, requesting details on the purpose of the planned Trump memecoin gala in April.

The organizers of the event are “dangling access” to Trump, the lawmakers said, according to Politico, which obtained a copy of the letter. 

Trump and his family members stand to benefit from increased sales of the Trump memecoin; attendees are required to hold TRUMP tokens to gain access to the event, the Senators said.

Advertisement

Magazine: Trump’s crypto ventures raise conflict of interest, insider trading questions